Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed mantle cell lymphoma~* Presenting with at least one of the following:~  * Coexpression of CD20 (or CD19) and CD5 and a lack of CD23 expression by immunophenotyping~ * Positive for cyclin D1 by immunostaining~ * Presence of t(11,14) by cytogenetic analysis~ * Molecular evidence of bcl-1/IgH rearrangement~* Stage I-IV disease~  * Stage III or IV if nodular histology mantle cell lymphoma present~ * Any stage for other mantle cell histologies~ * No mantle zone histology~* No active CNS disease~  * No symptomatic meningeal lymphoma~ * No known CNS parenchymal lymphoma~ * Lumbar puncture showing mantle cell lymphoma allowed~* Bidimensionally measurable disease greater than 1 cm~  * Nonmeasurable disease includes the following:~    * Bone lesions~   * Leptomeningeal disease~   * Ascites~   * Pleural/pericardial effusion~   * Inflammatory breast disease~   * Lymphangitis cutis/pulmonis~   * Abdominal masses not confirmed and followed by imaging techniques~   * Cystic lesions~   * Lesions in a previously irradiated area~PATIENT CHARACTERISTICS:~Age:~* 18 to 69~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Hepatitis B surface antigen and hepatitis C antibody positive patients must meet all of the following criteria:~  * Bilirubin no greater than 2 times upper limit of normal (ULN)~ * AST no greater than 3 times ULN~ * Liver biopsy shows no greater than grade 2 fibrosis and no cirrhosis~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* LVEF at least 45% by MUGA or echocardiogram~Other:~* No known hypersensitivity to murine products~* HIV negative~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No more than 1 prior dose of rituximab~Chemotherapy:~* No more than 1 prior cycle of chemotherapy~* At least 3 weeks since prior chemotherapy~* No other concurrent chemotherapeutic agents~Endocrine therapy:~* No chronic use of oral corticosteroids for ongoing medical condition~* No concurrent hormonal therapy except for non-lymphoma-related conditions (e.g., insulin for diabetes)~* Other concurrent corticosteroids for adrenal failure, diffuse alveolar hemorrhage, carmustine pneumonitis, or as an anti-emetic allowed~Radiotherapy:~* No prior radiotherapy for mantle cell lymphoma~* Concurrent palliative radiotherapy allowed~* Concurrent cranial radiotherapy for asymptomatic meningeal lymphoma allowed~Surgery:~* At least 2 weeks since prior major surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Chemo/immuno/autolog transplant (Type: EXPERIMENTAL): Intensive chemotherapy followed by autologous stem cell transplant and immunotherapy for mantle cell lymphoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete